Skip to main content
Top
Published in: International Journal of Clinical Oncology 11/2023

22-09-2023 | Kidney Cancer | Original Article

Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group

Authors: Shigemitsu Horie, Sei Naito, Shingo Hatakeyama, Shuya Kandori, Kazuyuki Numakura, Renpei Kato, Tomoyuki Koguchi, Shingo Myoen, Yoshihide Kawasaki, Akihiro Ito, Hisanobu Adachi, Yoshiyuki Kojima, Wataru Obara, Tomonori Habuchi, Hiroyuki Nishiyama, Chikara Ohyama, Norihiko Tsuchiya

Published in: International Journal of Clinical Oncology | Issue 11/2023

Login to get access

Abstract

Background

The Modified International Metastatic Renal Cell Carcinoma Dataset Consortium model (mIMDC) is a preoperative prognostic model for pT3cN0M0 renal cell carcinoma (RCC). This study aimed to validate the mIMDC and to construct a new model in a localized and locally advanced RCC (LLRCC).

Methods

A database was established (the Michinoku Japan Urological Cancer Study Group database) consisting of 79 patients who were clinically diagnosed with LLRCC (cT3b/c/4NanyM0) and underwent radical nephrectomy from December 2007 to May 2018. Using univariable and multivariable analyses, we retrospectively analyzed disease-free survival (DFS) and overall survival (OS) in this database, constructed a new prognostic model according to these results, and estimated the model fit using c-index on the new and mIMDC models.

Results

Independent poorer prognostic factors for both DFS and OS include the following: ≥ 1 Eastern Cooperative Oncology Group performance status, 2.0 mg/dL C-reactive protein, and > upper normal limit of white blood cell count. The median DFS in the favorable (no factor), intermediate (one factor), and poor-risk group (two or three factors) was 76.1, 14.3, and 4.0 months, respectively (P < 0.001). The 3-year OS in the favorable, intermediate, and poor-risk group were 92%, 44%, and 0%, respectively (P < 0.001). The c-indices of the new and mIMDC models were 0.67 and 0.60 for DFS (P = 0.060) and 0.74 and 0.63 for OS (P = 0.012), respectively.

Conclusion

The new preoperative prognostic model in LLRCC can be used in patient care and clinical trials.
Appendix
Available only for authorised users
Literature
11.
go back to reference Warren H, Fernando A, Thomas K et al (2019) Surgery for high-risk locally advanced (pT3c) renal tumours: oncological outcomes and prognostic significance of a modified International metastatic renal cell cancer database consortium (IMDC) score. BJU Int 124(3):462–468. https://doi.org/10.1111/bju.14755CrossRefPubMed Warren H, Fernando A, Thomas K et al (2019) Surgery for high-risk locally advanced (pT3c) renal tumours: oncological outcomes and prognostic significance of a modified International metastatic renal cell cancer database consortium (IMDC) score. BJU Int 124(3):462–468. https://​doi.​org/​10.​1111/​bju.​14755CrossRefPubMed
12.
go back to reference Kattan MW, Reuter V, Motzer RJ et al (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166(1):63–67CrossRefPubMed Kattan MW, Reuter V, Motzer RJ et al (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166(1):63–67CrossRefPubMed
27.
go back to reference Semeniuk-Wojtas A, Lubas A, Stec R et al (2018) Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive Protein as new and simple prognostic factors in patients with metastatic renal cell cancer treated with tyrosine kinase inhibitors: a systemic review and meta-analysis. Clin Genitourin Cancer 16(3):e685–e693. https://doi.org/10.1016/j.clgc.2018.01.010CrossRefPubMed Semeniuk-Wojtas A, Lubas A, Stec R et al (2018) Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive Protein as new and simple prognostic factors in patients with metastatic renal cell cancer treated with tyrosine kinase inhibitors: a systemic review and meta-analysis. Clin Genitourin Cancer 16(3):e685–e693. https://​doi.​org/​10.​1016/​j.​clgc.​2018.​01.​010CrossRefPubMed
Metadata
Title
Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group
Authors
Shigemitsu Horie
Sei Naito
Shingo Hatakeyama
Shuya Kandori
Kazuyuki Numakura
Renpei Kato
Tomoyuki Koguchi
Shingo Myoen
Yoshihide Kawasaki
Akihiro Ito
Hisanobu Adachi
Yoshiyuki Kojima
Wataru Obara
Tomonori Habuchi
Hiroyuki Nishiyama
Chikara Ohyama
Norihiko Tsuchiya
Publication date
22-09-2023
Publisher
Springer Nature Singapore
Published in
International Journal of Clinical Oncology / Issue 11/2023
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-023-02401-2

Other articles of this Issue 11/2023

International Journal of Clinical Oncology 11/2023 Go to the issue
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare